Home LiteratureArticle Details
PMID: 16043204 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.

Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine.

Virology ·Vol. 340 ·No. 2 ·2005-09-30 ·Pages 174-82

Kapadia SU, Rose JK, Lamirande E, Vogel L, Subbarao K, Roberts A

Abstract

Although the recent SARS coronavirus (SARS-CoV) that appeared in 2002 has now been contained, the possibility of re-emergence of SARS-CoV remains. Due to the threat of re-emergence, the overall fatality rate of approximately 10%, and the rapid dispersion of the virus via international travel, viable vaccine candidates providing protection from SARS are clearly needed. We developed an attenuated VSV recombinant (VSV-S) expressing the SARS coronavirus (SARS-CoV) spike (S) protein. In cells infected with this recombinant, S protein was synthesized, glycosylated at approximately 17 Asn residues, and transported via the Golgi to the cell surface. Mice vaccinated with VSV-S developed SARS-neutralizing antibody and were able to control a challenge with SARS-CoV performed at 1 month or 4 months after a single vaccination. We also demonstrated, by passive antibody transfer, that the antibody response induced by the vaccine was sufficient for controlling SARS-CoV infection. A VSV-vectored SARS vaccine could have significant advantages over other SARS vaccine candidates described to date.

MeSH Terms
Animals Antibody Formation Cell Line Cricetinae DNA Primers Immunity, Cellular Kidney Mice Reverse Transcriptase Polymerase Chain Reaction SARS Virus/genetics,immunology Severe Acute Respiratory Syndrome/immunology Vaccines, Attenuated Vaccines, DNA Vesicular stomatitis Indiana virus/immunology Viral Vaccines
Chemicals
DNA Primers Vaccines, Attenuated Vaccines, DNA Viral Vaccines
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Kapadia Sagar U
Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA.
Rose John K
Lamirande Elaine
Vogel Leatrice
Subbarao Kanta
Roberts Anjeanette
References (41)
41 references, click to expand
  1. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China.
    Science. 2003 Oct 10;302(5643):276-8 PMID: 12958366
  2. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus.
    Nature. 2003 Nov 27;426(6965):450-4 PMID: 14647384
  3. Immunogenicity of SARS inactivated vaccine in BALB/c mice.
    Immunol Lett. 2004 Sep;95(2):139-43 PMID: 15388253
  4. Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies.
    J Virol. 2000 May;74(10):4652-7 PMID: 10775601
  5. Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization.
    J Virol. 1990 Mar;64(3):1407-9 PMID: 2154621
  6. Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice.
    Vaccine. 2005 Jan 4;23(7):924-31 PMID: 15603894
  7. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice.
    J Virol. 2004 Apr;78(7):3572-7 PMID: 15016880
  8. Attenuated vesicular stomatitis viruses as vaccine vectors.
    J Virol. 1999 May;73(5):3723-32 PMID: 10196265
  9. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors.
    Lancet. 2004 Mar 20;363(9413):938-47 PMID: 15043961
  10. Complete protection from papillomavirus challenge after a single vaccination with a vesicular stomatitis virus vector expressing high levels of L1 protein.
    J Virol. 2004 Mar;78(6):3196-9 PMID: 14990742
  11. Humoral immune responses in rabbits induced by an experimental inactivated severe acute respiratory syndrome coronavirus vaccine prepared from F69 strain.
    Chin Med J (Engl). 2004 Nov;117(11):1625-9 PMID: 15569476
  12. Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice.
    DNA Cell Biol. 2004 Jun;23(6):391-4 PMID: 15231072
  13. The Genome sequence of the SARS-associated coronavirus.
    Science. 2003 May 30;300(5624):1399-404 PMID: 12730501
  14. Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes.
    AIDS Res Hum Retroviruses. 2004 Sep;20(9):989-1004 PMID: 15585086
  15. Cutting edge: long-term B cell memory in humans after smallpox vaccination.
    J Immunol. 2003 Nov 15;171(10):4969-73 PMID: 14607890
  16. Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein.
    Biochem Biophys Res Commun. 2004 Jul 2;319(3):746-52 PMID: 15184046
  17. A novel coronavirus associated with severe acute respiratory syndrome.
    N Engl J Med. 2003 May 15;348(20):1953-66 PMID: 12690092
  18. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge.
    J Virol. 1998 Jun;72(6):4704-11 PMID: 9573234
  19. Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides.
    Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60 PMID: 15150417
  20. A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice.
    Int Immunol. 2004 Oct;16(10):1423-30 PMID: 15314040
  21. The S1 glycoprotein but not the N or M proteins of avian infectious bronchitis virus induces protection in vaccinated chickens.
    Arch Virol. 1994;138(1-2):117-34 PMID: 7980002
  22. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS.
    Lancet. 2004 Jun 26;363(9427):2122-7 PMID: 15220033
  23. Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase.
    Proc Natl Acad Sci U S A. 1986 Nov;83(21):8122-6 PMID: 3095828
  24. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region.
    J Virol. 2005 Mar;79(5):2678-88 PMID: 15708987
  25. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus.
    Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15748-53 PMID: 15496474
  26. Identification of a novel coronavirus in patients with severe acute respiratory syndrome.
    N Engl J Med. 2003 May 15;348(20):1967-76 PMID: 12690091
  27. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets.
    J Virol. 2004 Nov;78(22):12672-6 PMID: 15507655
  28. Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets.
    Vaccine. 2005 Mar 18;23(17-18):2273-9 PMID: 15755610
  29. Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge.
    J Virol. 2001 Nov;75(22):11079-87 PMID: 11602747
  30. The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus.
    J Virol. 1996 Apr;70(4):2318-23 PMID: 8642658
  31. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice.
    Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6641-6 PMID: 15096611
  32. Epitope specificity of protective lactogenic immunity against swine transmissible gastroenteritis virus.
    J Virol. 1992 Nov;66(11):6502-8 PMID: 1383566
  33. Characterization of a novel coronavirus associated with severe acute respiratory syndrome.
    Science. 2003 May 30;300(5624):1394-9 PMID: 12730500
  34. Effects of a SARS-associated coronavirus vaccine in monkeys.
    Lancet. 2003 Dec 6;362(9399):1895-6 PMID: 14667748
  35. Mouse hepatitis virus spike and nucleocapsid proteins expressed by adenovirus vectors protect mice against a lethal infection.
    J Gen Virol. 1993 Oct;74 ( Pt 10):2061-9 PMID: 8409930
  36. Resistance of naive mice to murine hepatitis virus strain 3 requires development of a Th1, but not a Th2, response, whereas pre-existing antibody partially protects against primary infection.
    J Immunol. 1996 May 1;156(9):3342-9 PMID: 8617959
  37. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice.
    Nature. 2004 Apr 1;428(6982):561-4 PMID: 15024391
  38. Severe acute respiratory syndrome.
    Nat Med. 2004 Dec;10(12 Suppl):S88-97 PMID: 15577937
  39. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants.
    Cell. 2001 Sep 7;106(5):539-49 PMID: 11551502
  40. Recombinant vesicular stomatitis viruses from DNA.
    Proc Natl Acad Sci U S A. 1995 May 9;92(10):4477-81 PMID: 7753828
  41. Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry.
    Biochem Biophys Res Commun. 2004 Dec 10;325(2):445-52 PMID: 15530413
Article Info
Journal
Virology
Abbr.
Virology
ISSN
0042-6822
DOI
10.1016/j.virol.2005.06.016
Published
2005-09-30
Pages
174-82
Language
English
Region
United States
NLM ID
0110674
PMCID
PMC7111745
Subset
IM
Grants
NIAID NIH HHS · U54 AI057158 · United States
NIAID NIH HHS · AI057158 · United States
External Links
PubMed source DOI: 10.1016/j.virol.2005.06.016 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2